Barry Cohen, MD
Nephrology · Trenton, NJNPI 1104856616
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $690 and has fallen 53.1% since, to $324 in 2025.
Across 131 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$420
- Bayer$334
- Vifor Pharma, Inc.$230
- OPKO Pharmaceuticals, LLC$224
- Akebia Therapeutics Inc$146
- Otsuka America Pharmaceutical, Inc.$134
- plus $674 from 11 others
What the payments were for
- Food & beverage$2,162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 28 | $420 |
| Bayer | 20 | $334 |
| Vifor Pharma, Inc. | 13 | $230 |
| OPKO Pharmaceuticals, LLC | 11 | $224 |
| Akebia Therapeutics Inc | 9 | $146 |
| Otsuka America Pharmaceutical, Inc. | 9 | $134 |
| Ardelyx, Inc. | 7 | $124 |
| Calliditas Therapeutics US Inc. | 5 | $93 |
| AstraZeneca | 5 | $85 |
| Daiichi Sankyo Inc. | 5 | $85 |
| Novartis | 5 | $80 |
| Mallinckrodt Hospital Products Inc. | 5 | $76 |
| Amgen | 3 | $46 |
| Aurinia Pharma U.S., Inc. | 3 | $43 |
| Sanofi | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$2,162 in reported general payments places this provider in the 65th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 18 | $2,453 |
| Clonidine Hcl | 21 | $398 |
| Amlodipine Besylate | 43 | $166 |
| Rosuvastatin Calcium | 17 | $124 |
| Ezetimibe | 14 | $113 |
| Losartan Potassium | 21 | $97 |
| Furosemide | 25 | $88 |
| Atorvastatin Calcium | 11 | $64 |
| Metoprolol Succinate | 19 | $61 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Trenton
- Asher HussainTrenton$6K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.